lonafarnib has been researched along with Angiogenesis, Pathologic in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, Y; Peng, G; Qin, J; Sun, L; Wang, J; Xie, S; Zhong, D | 1 |
| Aggarwal, BB; Khuri, FR; Takada, Y | 1 |
| Han, JY; Hong, WK; Kim, E; Lee, HY; Morgillo, F; Myers, JN; Oh, SH | 1 |
| Cohen, P; El-Naggar, AK; Hong, WK; Khuri, F; Kies, M; Kim, JH; Kim, WY; Lee, HY; Myers, JN; Oh, SH; Younes, MN | 1 |
4 other study(ies) available for lonafarnib and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Lonafarnib is a potential inhibitor for neovascularization.
Topics: Alkyl and Aryl Transferases; Animals; Apolipoproteins E; Atherosclerosis; Cell Polarity; Cell Proliferation; Cytoskeletal Proteins; Endothelial Cells; Gene Expression Regulation; Humans; Mice; Neovascularization, Pathologic; Piperidines; Pyridines | 2015 |
Protein farnesyltransferase inhibitor (SCH 66336) abolishes NF-kappaB activation induced by various carcinogens and inflammatory stimuli leading to suppression of NF-kappaB-regulated gene expression and up-regulation of apoptosis.
Topics: Active Transport, Cell Nucleus; Alkyl and Aryl Transferases; Apoptosis; Blotting, Western; Carcinogens; Cell Division; Cell Line, Tumor; Cell Survival; Cytoplasm; DNA; Dose-Response Relationship, Drug; Enzyme Activation; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Humans; Hydrogen Peroxide; I-kappa B Kinase; Immunohistochemistry; In Situ Nick-End Labeling; Inflammation; Jurkat Cells; Models, Chemical; Neovascularization, Pathologic; NF-kappa B; Okadaic Acid; Phosphorylation; Piperidines; Protein Binding; Protein Serine-Threonine Kinases; Pyridines; ras Proteins; Smoking; Time Factors; Tumor Necrosis Factor-alpha; Up-Regulation | 2004 |
Hypoxia-inducible factor 1alpha and antiangiogenic activity of farnesyltransferase inhibitor SCH66336 in human aerodigestive tract cancer.
Topics: Alkyl and Aryl Transferases; Angiogenesis Inhibitors; Animals; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Enzyme Inhibitors; Farnesyltranstransferase; Female; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; HSP90 Heat-Shock Proteins; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Immunohistochemistry; Immunoprecipitation; Lung Neoplasms; Mice; Mice, Nude; Mitogen-Activated Protein Kinase Kinases; Neovascularization, Pathologic; Phosphatidylinositol 3-Kinases; Piperidines; Proteasome Endopeptidase Complex; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Pyridines; Reverse Transcriptase Polymerase Chain Reaction; Transcription Factors; Ubiquitin; Up-Regulation; Vascular Endothelial Growth Factor A | 2005 |
Identification of insulin-like growth factor binding protein-3 as a farnesyl transferase inhibitor SCH66336-induced negative regulator of angiogenesis in head and neck squamous cell carcinoma.
Topics: Animals; Aorta; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Proliferation; Chickens; Chorioallantoic Membrane; Endothelium, Vascular; Enzyme Inhibitors; Farnesyltranstransferase; Female; Gene Expression Regulation, Neoplastic; Genes, ras; Head and Neck Neoplasms; Humans; Insulin-Like Growth Factor Binding Protein 3; Mice; Mice, Nude; Neovascularization, Pathologic; Piperidines; Pyridines; rhoB GTP-Binding Protein; Tumor Cells, Cultured; Umbilical Veins; Vascular Endothelial Growth Factor A | 2006 |